SCHEMBL13352145

SCHEMBL13352145

CCCOc1cc(/C=C/C(=O)Nc2ccccc2C)ccc1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.66
KMT2A Q03164 4/20 0.66
CYP3A4 P08684 3/20 0.66
CYP2C19 P33261 2/20 0.66
ALDH1A1 P00352 2/20 0.60
TP53 P04637 2/20 0.60
HPGD P15428 2/20 0.60
HIF1A Q16665 2/20 0.60
PKM P14618 2/20 0.60
KDM4E B2RXH2 2/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPK1 P28482 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
HSD17B10 Q99714 1/20 0.60
ABCC4 O15439 1/20 0.60
HPGDS O60760 1/20 0.60
ABCB11 O95342 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13352144 0.96 MEN1 (0.71) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL13352016 0.89 MEN1 (0.74) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL297188 0.89 MEN1 (0.74) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL13352164 0.89 MEN1 (0.56) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL14319164 0.88 MEN1 (0.58) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL13352107 0.88 MEN1 (0.80) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL13352092 0.87 PKM (0.56) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL13352033 0.86 APP (0.64) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL13352096 0.86 PKM (0.55) MEN1KMT2ACYP3A4CYP2C19ALDH1A1
SCHEMBL9607343 0.85 PKM (0.59) MEN1KMT2ACYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC MEN1 2640/4885KMT2A 1798/4885CYP3A4 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.